Consistent safety profile with up to five years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Journal of the American Academy of Dermatology | Nov 21, 2021